Research location

Garden Grove

California, United States

Published trials403
Site observations407
Linked trials published403
Page1 / 9

Research activity in Garden Grove

California, United States

CureCurrent currently publishes aggregate city-level research activity for this location: 403 trials and 407 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Garden Grove

403 linked trials · page 1 of 9
Relapse Prevention Trial Evaluating KarXT Treatment in SchizophreniaNCT07686263 · 2026-08-20 · 1 site observation
RECRUITING
A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes MellitusNCT07662213 · 2026-07-06 · 1 site observation
RECRUITING
An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.NCT07543120 · 2026-05-07 · 1 site observation
RECRUITING
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428 · 2026-04-23 · 1 site observation
RECRUITING
A Long-Term Open-Label Study of ML-007C-MA in Adults With SchizophreniaNCT07459647 · 2026-03-31 · 1 site observation
RECRUITING
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute SchizophreniaNCT07363577 · 2026-03-25 · 1 site observation
RECRUITING
A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With SchizophreniaNCT07615426 · 2026-03-02 · 1 site observation
RECRUITING
A Study of Brenipatide in Adult Participants With SchizophreniaNCT07410507 · 2026-02-10 · 1 site observation
RECRUITING
Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305 · 2026-01-23 · 1 site observation
RECRUITING
A Study to Evaluate the Effect of KarXT on Urological SafetyNCT07221877 · 2026-01-20 · 1 site observation
RECRUITING
Double-blind, Placebo-controlled Study in Adults With Major Depressive DisorderNCT07226661 · 2026-01-19 · 1 site observation
RECRUITING
Efficacy of NBI-1117568 in Preventing Relapse in Adults With SchizophreniaNCT07227818 · 2025-12-16 · 1 site observation
RECRUITING
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With SchizophreniaNCT07105098 · 2025-08-11 · 1 site observation
RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745 · 2025-07-16 · 1 site observation
RECRUITING
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With SchizophreniaNCT07114874 · 2025-07-11 · 1 site observation
RECRUITING
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)NCT07065240 · 2025-06-19 · 1 site observation
RECRUITING
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)NCT06883305 · 2025-03-18 · 1 site observation
RECRUITING
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 · 2025-03-03 · 1 site observation
RECRUITING
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)NCT06786624 · 2025-01-22 · 1 site observation
RECRUITING
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)NCT06524830 · 2024-12-30 · 1 site observation
RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's DementiaNCT06651567 · 2024-10-22 · 1 site observation
RECRUITING
Study of ALTO-101 in Patients With SchizophreniaNCT06502964 · 2024-06-11 · 1 site observation
RECRUITING
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)NCT05485961 · 2024-04-27 · 3 site observations
RECRUITING
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseaseNCT06283966 · 2024-02-21 · 1 site observation
RECRUITING
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum DisorderNCT06229210 · 2024-01-25 · 1 site observation
RECRUITING
ACP-204 in Adults With Alzheimer's Disease PsychosisNCT06159673 · 2023-11-14 · 1 site observation
RECRUITING
Safety and Efficacy of Brilaroxazine (RP5063) in SchizophreniaNCT05184335 · 2022-01-24 · 1 site observation
RECRUITING
A Study to Evaluate BMS-986511 in Adults With Major Depressive DisorderNCT07772531 · 2026-10-30 · 1 site observation
NOT_YET_RECRUITING
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or ObesityNCT07575932 · 2026-05-11 · 1 site observation
ACTIVE_NOT_RECRUITING
Reformulated PG324 Ophthalmic Solution for Intraocular Pressure ReductionNCT07082816 · 2025-09-02 · 1 site observation
COMPLETED
An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)NCT07161700 · 2025-09-02 · 1 site observation
ENROLLING_BY_INVITATION
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With SchizophreniaNCT07038876 · 2025-06-27 · 1 site observation
COMPLETED
An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With SchizophreniaNCT06924255 · 2025-04-01 · 1 site observation
NOT_YET_RECRUITING
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsNCT06857955 · 2025-03-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With SchizophreniaNCT06894212 · 2025-02-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive DisorderNCT06785012 · 2024-12-26 · 1 site observation
COMPLETED
Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle WeaknessNCT06600581 · 2024-12-19 · 1 site observation
ACTIVE_NOT_RECRUITING
Next Generation RocklatanNCT06441643 · 2024-09-04 · 1 site observation
COMPLETED
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major DepressionNCT06570369 · 2024-08-22 · 1 site observation
COMPLETED
Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)NCT06423781 · 2024-08-01 · 1 site observation
COMPLETED
Study of SPG302 in Adults With SchizophreniaNCT06442462 · 2024-08-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety Study of BHV-7000 Monotherapy in Major DepressionNCT06419608 · 2024-05-28 · 1 site observation
COMPLETED
To Evaluate the Effects of NMRA-335140 on Symptoms of Major Depression in Participants With Bipolar II Disorder.NCT06429722 · 2024-05-13 · 1 site observation
COMPLETED
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyNCT06194799 · 2024-04-23 · 1 site observation
ENROLLING_BY_INVITATION
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)NCT06272487 · 2024-02-29 · 1 site observation
COMPLETED
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06058013 · 2023-12-20 · 1 site observation
COMPLETED
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute SchizophreniaNCT06179108 · 2023-11-29 · 1 site observation
COMPLETED
Study to Assess the Safety and Effectiveness of NMRA-335140-501NCT06029439 · 2023-11-10 · 1 site observation
TERMINATED
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNCT06107803 · 2023-10-13 · 1 site observation
COMPLETED
Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive DisorderNCT06029426 · 2023-09-20 · 1 site observation
COMPLETED

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.